Updated: Aug 7, 2020
Recent acquisition of Celgene added debt and shares outstanding but also increased revenues substantially
PE ratio misleading due to one time acquisition charges.
BMY has strong portfolio of drugs aimed at fighting cancer. Generally, the FDA is more likely to approve cancer drugs vs other categories.
BMY's Opdivo and Merck's Keytruda are the best two cancer treatments on the market. I say; own BMY, and own MRK too.